You searched for " retina"
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...How a calcified Soemmerring ring was removed from the vitreous cavity when the cutter and forceps failed to do so
Know’st thou the land where lemon-trees do bloom,And oranges like gold in leafy gloom; A gentle wind from deep blue heaven blows, The myrtle thick, and high the laurel grows? ‘Tis there! ‘tis there, O my beloved one, I with...Defence Medical Services Ophthalmology Conference 2024
by Dr Ben Smith, General Duties Medical Officer (Army), Tidworth, UK. This annual national meeting of tri-service defence ophthalmologists was held in the beautiful and historic setting of Merton College in Oxford, hosted by Professor Robert MacLaren, the current Professor...27th Nottingham Eye Symposium and Research Meeting
A unique opportunity for the dissemination and discussion of cutting-edge basic science and clinical ophthalmic research. Conference Chair: Ms. Dalia Said The 27th Nottingham Eye Symposium & Research Meeting anticipates a delegation of approx. 150 ophthalmologists from around the UK...Intravitreal injections delivered by ophthalmic clinical nurse specialists
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...Safety and efficacy of a nurse-led intravitreal injection service using an Precivia® injection assist device
Nurse-led intravitreal injections have become of great importance for busy eye units. In this article, the authors present safety data from five years of a nurse-led service with the use of the Precivia® intravitreal injection assist device. Intravitreal injections of...Genetic profiling for personalised healthcare solutions in AMD – an update
Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...Psychiatric Consequences of Ophthalmic Disease
In part two of this series on ophthalmology and psychiatry, the authors will cover the possible psychiatric consequences of ophthalmic disease. The following conditions will be discussed: a. Black patch psychosis b. Psychological state in blindness c. Phobias in the...Line-up confirmed for Eye News Symposium!
We are delighted to confirm an excellent line-up of speakers and topics for the Eye News Symposium, taking place in Glasgow on Sunday 20 January.
Fingolimod: ocular adverse effects
In this article the authors review the ocular side-effects of Fingolimod which is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular oedema (FAME) is the most common ocular side-effect linked to this drug....
Intravitreal dexamethasone implant for recurrent CMO secondary to IGS
In this prospective study the authors present the data obtained on the efficacy and safety of the dexamethasone implant (0.7 mg) in the treatment of recurrent cystoid macular oedema (PCME) due to Irvine–Gass syndrome in patients with uncomplicated pseudophakia (off-label...
